Table 3:
The treatment response and clinical outcomes in our AML cohort of patients with del(7) or del(7q) treated with or without Venetoclax.
| Characteristic | Overall, N = 243 | del(7) Others, N = 137 | del(7) Ven, N = 31 | del(7q) Others, N = 67 | del(7q) Ven, N = 8 | p-value1 |
|---|---|---|---|---|---|---|
| Age (years), Mean+/−SD; Median (Range) | 67.5+/−12.6; 70.3 (23.4 – 87.8) | 67.6+/−11.8; 70.2 (26.3 – 87.8) | 67.3+/−13.6; 70.0 (23.4 – 85.7) | 67.3+/−14.4; 71.0 (25.0 – 84.2) | 69.9+/−6.5; 71.7 (59.3 – 78.3) | >0.9 |
| Gender, n/N (%) | ||||||
| Female | 100/243 (41%) | 62/137 (45%) | 12/31 (39%) | 21/67 (31%) | 5/8 (62%) | |
| Male | 143/243 (59%) | 75/137 (55%) | 19/31 (61%) | 46/67 (69%) | 3/8 (38%) | |
| Cytogenetics, n/N (%) | 0.9 | |||||
| Complex (>=3) | 168/243 (69%) | 94/137 (69%) | 20/31 (65%) | 48/67 (72%) | 6/8 (75%) | |
| Other (<3) | 75/243 (31%) | 43/137 (31%) | 11/31 (35%) | 19/67 (28%) | 2/8 (25%) | |
| ELN based on Cytogenetics, n/N (%) | <0.001 | |||||
| Non-poor | 21/243 (8.6%) | 0/137 (0%) | 0/31 (0%) | 19/67 (28%) | 2/8 (25%) | |
| Poor | 222/243 (91%) | 137/137 (100%) | 31/31 (100%) | 48/67 (72%) | 6/8 (75%) | |
| Secondary AML, n/N (%) | 0.5 | |||||
| De novo AML | 142/243 (58%) | 78/137 (57%) | 18/31 (58%) | 43/67 (64%) | 3/8 (38%) | |
| Secondary AML | 101/243 (42%) | 59/137 (43%) | 13/31 (42%) | 24/67 (36%) | 5/8 (62%) | |
| TP53 Mutations, n/N (%) | 0.6 | |||||
| TP53 wild type | 81/178 (46%) | 45/93 (48%) | 11/31 (35%) | 22/46 (48%) | 3/8 (38%) | |
| TP53 mutant | 97/178 (54%) | 48/93 (52%) | 20/31 (65%) | 24/46 (52%) | 5/8 (62%) | |
| Unknown | 65 | 44 | 0 | 21 | 0 | |
| Chr17/17p Loss, n/N (%) | 56/243 (23%) | 30/137 (22%) | 5/31 (16%) | 19/67 (28%) | 2/8 (25%) | 0.6 |
| Venetoclax, n/N (%) | 39/243 (16%) | 0/137 (0%) | 31/31 (100%) | 0/67 (0%) | 8/8 (100%) | <0.001 |
| Intensity, n/N (%) | 0.3 | |||||
| High Intensity | 60/243 (25%) | 36/137 (26%) | 4/31 (13%) | 19/67 (28%) | 1/8 (12%) | |
| Low Intensity | 183/243 (75%) | 101/137 (74%) | 27/31 (87%) | 48/67 (72%) | 7/8 (88%) | |
| Best Response, n/N (%) | 0.4 | |||||
| CR | 92/243 (38%) | 52/137 (38%) | 12/31 (39%) | 24/67 (36%) | 4/8 (50%) | |
| CRi | 26/243 (11%) | 14/137 (10%) | 5/31 (16%) | 5/67 (7.5%) | 2/8 (25%) | |
| NR | 125/243 (51%) | 71/137 (52%) | 14/31 (45%) | 38/67 (57%) | 2/8 (25%) |
1
Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test